MARKET WIREYahoo! Finance Canada • 1d ago
InterCure Ltd. (INCR) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
Why INCR Stock surged +2.02% Today — RQD Quant Desk Flash
$4.05 +2.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.06
Intercure Ltd. (INCR) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $60.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on INCR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is INCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Intercure Ltd. (NASDAQ: INCR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $4.05 (+2.02% 1D, market cap $60.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, INCR ranks #339 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does INCR compare to SPRO and APLM in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INCR carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SPRO (Spero Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E 7.5x, ROIC 26.6%, cap $60.6M) and APLM (Apollomics Inc. (Class A)) posts a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $60.4M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for INCR?
▼
For Intercure Ltd. (INCR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #339 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.06 (+0.17%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INCR)Realized 20D OHLCV Swing Band: ±9.8%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY INCR SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)
SEC XBRL Trailing 12 Months: 0% FCF Margin ($1.7M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$5.03-11.9% Next Q
54
Q2 (-2Q)Grade C-$4.43+0.9% Next Q
51
Q3 (-1Q)Grade D$4.47-9.4% Next Q
49
CurrentGrade D$4.05-6.1% Hist 90D α
46
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a INCR Turnaround Squeeze
While INCR currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.05) and Max Pain ($4.25) forces dealer call-delta covering toward $7.93.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $INCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INCR Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why INCR Stock surged +2.02% Today — RQD Quant Desk Flash
Intercure Ltd. (INCR) surged +2.02% to $4.05, trading at 16% of its 52-week range ($3.4 – $7.55). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 16% of its 52-week range ($3.4 – $7.55) with RSI-14 at 32.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.8% around $4.05 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $1.7M annual free cash flow.
Live INCR Headlines & Catalysts
MARKET WIRETradingView • 1d ago
InterCure Ltd. Estimates – TASE:INCRTradingView report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 2d ago
Intercure (INCR) Slides 3.57% to $5.13 as Shares Drift Toward Lower Support - Float Adjusted Caphttps://www.siam.in/ report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Top U.S. Stock Losers: Biggest Price DeclinesTradingKey report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Most Active Stocks Today: U.S. MarketTradingKey report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 2d ago
InterCure Ltd. (INCR) Stock Price Prediction for 2026, 2030-2040Traders Union report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 2d ago
InterCure Ltd. Stock Price Today | INCR Live Chart & NewsTraders Union report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INCR)
- ✓Walkthrough of INCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
INCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.25%🛡️ HOLDING TREND SUPPORT
2026-11-04O $3.97H $4.05L $3.97C $4.05VOL 12.2K
RES: $6.41SUP: $3.96SMA50: $5.05SMA200: $4.61
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
INCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on INCR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for INCR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INCR)
Health Care Rank #339 of 1015
⚔️ SPRO vs INCR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (INCR vs. SPRO, APLM, OSTX, ZYBT)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Intercure Ltd. (INCR) ranks #339 by composite RQD confidence (46/100, grade D) and #712 by equity capitalization ($60.8M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. APLM currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with INCR at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INCR
ACTIVE
Intercure Ltd. | D | 46/100 | — | — | — | +2.02% | $60.8M | Benchmark Subject |
| SPRO Spero Therapeutics Inc. | D- | 40/100 | 7.5x | — | 26.6% | -1.89% | $60.6M | /spro-vs-incr → |
| APLM Apollomics Inc. (Class A) | D+ | 55/100 | — | — | — | +0.73% | $60.4M | /aplm-vs-incr → |
| OSTX OS Therapies Incorporated | E | 30/100 | — | — | -35.0% | -7.26% | $59.8M | /ostx-vs-incr → |
| ZYBT Zhengye Biotechnology Holding Limited (Class A) | D- | 41/100 | — | 20.5% | -22.3% | +2.31% | $63.0M | /zybt-vs-incr → |
2. INCR Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTIntercure Ltd. (INCR) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $60.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. INCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs INCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Intercure Ltd. (NASDAQ: INCR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $4.05 (+2.02% 1D, market cap $60.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, INCR ranks #339 in composite RQD confidence.
How does INCR compare to SPRO and APLM in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INCR carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SPRO (Spero Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E 7.5x, ROIC 26.6%, cap $60.6M) and APLM (Apollomics Inc. (Class A)) posts a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $60.4M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for INCR?
For Intercure Ltd. (INCR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #339 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is INCR trading relative to its 50-day, 200-day, and 52-week technical levels?
INCR last traded at $4.05 (+2.02% on volume of 12,159 shares), positioning the stock -19.80% below its 50-day simple moving average ($5.05) and -12.15% below its 200-day simple moving average ($4.61). Across its 52-week range of $3.40 to $7.55, INCR sits at the 15.7% percentile with a 14-day RSI of 32.1 (NEUTRAL RANGE) and an implied next-earnings move of ±9.8% ($3.65 to $4.45).
ROARABLE RATING BRIEF • RQD 46/100 (D)
✓ SEC XBRL & RQD VERIFIED
INCR — Intercure Ltd.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
Intercure Ltd. (INCR) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $4.05 (+2.02% 1D, market capitalization $60.8M).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
. (INCR) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The source data describes the company's market capitalization as $0.1B.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.40 – $7.55 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Sector correlation data beyond the Health Care sector classification and the beta of 1. Second-order bottlenecks cannot be identified from the source data.
- Key Question #1: Can INCR sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $7.55 52-week high?
- Key Question #3: How sensitive is INCR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
INCR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Intercure Ltd. (INCR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
InterCure Ltd. (INCR) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
InterCure Ltd. Estimates – TASE:INCR TradingView report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 2d ago
Intercure (INCR) Slides 3.57% to $5.13 as Shares Drift Toward Lower Support - Float Adjusted Cap https://www.siam.in/ report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Top U.S. Stock Losers: Biggest Price Declines TradingKey report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Most Active Stocks Today: U.S. Market TradingKey report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 2d ago
InterCure Ltd. (INCR) Stock Price Prediction for 2026, 2030-2040 Traders Union report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 2d ago
InterCure Ltd. Stock Price Today | INCR Live Chart & News Traders Union report covering Intercure Ltd. (INCR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
INCR Bull vs. Bear Conversation Board — What's Your Call at $4.05?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INCR 🐻 33% BEARISH CONVICTION
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH
🎯 Target: $4.72 (+18.9%)
📌 Pinned Debate The forensic balance sheet pillar scores 13 of 20, supported by an Altman Z-Score of 2.5 and a Piotroski F-Score of 6/9.
Don't sleep on INCR's setup in Health Care. The forensic balance sheet pillar scores 13 of 20, supported by an Altman Z-Score of 2.5 and a Piotroski F-Score of 6/9.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (46/100) backs up the fundamental quality.
VolSurface_Trader 🐂 BULL
Both sides have a point here — INCR's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH
🎯 Target: $3.22 (-18.9%)
Spot @ $3.97 The RQD verdict is Roarable Sell, with ROIC and FCF yield both at 0% and institutional flow scoring just 4 of 20.
Sitting on the sidelines or leaning short INCR above $3.97. The RQD verdict is Roarable Sell, with ROIC and FCF yield both at 0% and institutional flow scoring just 4 of 20.. Until Fundamental Cash Engine (12/20) and FCF yield (0.0%) inflect higher, upside is capped near $7.55.